The three currently approved CD‐19‐directed CAR‐T in LBCL (i.e., axi‐cel, tisa‐cel, and liso‐cel) are being actively investigated in patients with PCNSL and SCNSL (NCT04608487) (NCT04134117) (NCT03484702); results are currently awaited. The gene discussed is CD19; the disease is primary central nervous system lymphoma.